RxDoctor Payments Data

John Wise, MD

Internal Medicine · New Orleans, LANPI 1477556496

Payments from drug & device makers

$10,853in general payments, 2019–2025

Across 601 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Viiv Healthcare Company$1K
  • Pfizer$1K
  • Lilly USA, LLC$883
  • Amgen$638
  • AstraZeneca$560
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$10,65298%
  • Education$2012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,853 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$43,630
Medicare patients
85
Services billed
1,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban208$88,363
TrulicityDulaglutide43$46,176
XareltoRivaroxaban45$28,822
TivicayDolutegravir Sodium12$25,464
IsentressRaltegravir Potassium12$22,524
JardianceEmpagliflozin38$20,072
MounjaroTirzepatide17$17,610
RestasisCyclosporine26$11,037
RexultiBrexpiprazole13$9,205
JanuviaSitagliptin Phosphate52$7,482
NamzaricMemantine Hcl/Donepezil Hcl16$4,699
Cyclosporine24$4,688
PremarinEstrogens, Conjugated11$4,500
Atorvastatin Calcium232$4,446
MyrbetriqMirabegron19$4,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$1,061$92,863219 claims
Lilly USA, LLCTrulicity, Mounjaro$883$63,78660 claims
MerckIsentress, Januvia$286$30,00564 claims
Johnson & JohnsonXarelto$149$28,82245 claims
Viiv Healthcare CompanyTivicay$1,068$25,46412 claims
AbbVieRestasis, Namzaric, Synthroid$2,167$17,51965 claims
Astellas Pharma US IncMyrbetriq$292$4,15619 claims
Sanofi-aventis U.S. LLCLantus$69$3,67735 claims
AstraZenecaFarxiga$560$3,39412 claims
Almatica Pharma LLCSertraline Hcl$41$2,042122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →